Javier Chaparro‐Riggers

3.9k total citations
41 papers, 2.0k citations indexed

About

Javier Chaparro‐Riggers is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Javier Chaparro‐Riggers has authored 41 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 18 papers in Oncology and 18 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Javier Chaparro‐Riggers's work include Monoclonal and Polyclonal Antibodies Research (18 papers), CAR-T cell therapy research (15 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Javier Chaparro‐Riggers is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (18 papers), CAR-T cell therapy research (15 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Javier Chaparro‐Riggers collaborates with scholars based in United States, Germany and Russia. Javier Chaparro‐Riggers's co-authors include Andreas S. Bommarius, Karen M. Polizzi, James M. Broering, Kevin C. Lindquist, Bettina Bommarius, Pavel Strop, Yik A. Yeung, Arvind Rajpal, Sherman M. Chin and Andrea Rossi and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Javier Chaparro‐Riggers

41 papers receiving 2.0k citations

Peers

Countries citing papers authored by Javier Chaparro‐Riggers

Since Specialization

Citations

This map shows the geographic impact of Javier Chaparro‐Riggers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Chaparro‐Riggers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Chaparro‐Riggers more than expected).

Fields of papers citing papers by Javier Chaparro‐Riggers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Chaparro‐Riggers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Chaparro‐Riggers. The network helps show where Javier Chaparro‐Riggers may publish in the future.

Co-authorship network of co-authors of Javier Chaparro‐Riggers

This figure shows the co-authorship network connecting the top 25 collaborators of Javier Chaparro‐Riggers. A scholar is included among the top collaborators of Javier Chaparro‐Riggers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Chaparro‐Riggers. Javier Chaparro‐Riggers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structural elucidation of the haptoglobin–hemoglobin clearance mechanism by macrophage scavenger receptor CD163 2025 ·PLoS Biology ·(unknown), Hui Wang, Joshua B. White, (unknown), Cindy Huynh, Kristoffer Brännström, Mark Horn, Stephen P. Muench, W.S. Somers, Javier Chaparro‐Riggers, Laura Lin, Lidia Mosyak	1
2	Characterization of the BCMA epitope bound by BCMA-CD3 T cell engager elranatamab. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Lidia Mosyak, Javier Chaparro‐Riggers, Bas Baaten, (unknown)	2
3	Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeys 2024 ·PLoS ONE ·Changhua Ji, Bing Kuang, Bernard S. Buetow, Allison Vitsky, Yuanming Xu, Tzu-Hsuan Huang, Javier Chaparro‐Riggers, Eugenia Kraynov, (unknown)	3
4	Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling 2022 ·Cancer Immunology Research ·Regina Lin, Andrew R. Nager, Spencer Park, Janette Sutton, (unknown), Zea Melton, (unknown), Bijan Boldajipour, Thomas Van Blarcom, Siler H. Panowski, Barbra J. Sasu, Javier Chaparro‐Riggers	6
5	Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma 2022 ·Cancer Research ·Siler H. Panowski, (unknown), Nguyêñ Duy Tân, Silvia K. Tacheva-Grigorova, B. Smith, Yvonne S.L. Mak, (unknown), (unknown), Dinali Wijewarnasuriya, (unknown), Zea Melton, (unknown), Mathilde Dusséaux, Román Galetto, (unknown), Tao Sai, Thomas Van Blarcom, Javier Chaparro‐Riggers, Barbra J. Sasu	57
6	Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity 2021 ·Journal for ImmunoTherapy of Cancer ·(unknown), Pawel K. Dominik, (unknown), Sheng Ding, Wenjing Yang, Nadia S. Kurd, (unknown), Jonathan R. Heyen, (unknown), Zea Melton, Thomas Van Blarcom, Kevin C. Lindquist, Javier Chaparro‐Riggers, Shahram Salek‐Ardakani	96
7	Structural delineation and phase-dependent activation of the costimulatory CD27:CD70 complex 2021 ·Journal of Biological Chemistry ·Weifeng Liu, (unknown), (unknown), Kevin C. Lindquist, Manqing Li, Vinayak Rayannavar, (unknown), Andrew R. Nager, Edward Pascua, Pawel K. Dominik, David Oyen, Hui Wang, (unknown), (unknown), Lidia Mosyak, Javier Chaparro‐Riggers	8
8	Direct control of CAR T cells through small molecule-regulated antibodies 2021 ·Nature Communications ·Spencer Park, Edward Pascua, Kevin C. Lindquist, Christopher R. Kimberlin, Xiaodi Deng, Yvonne S.L. Mak, Zea Melton, Theodore Johnson, Regina Lin, Bijan Boldajipour, Robert T. Abraham, Jaume Pons, Barbra J. Sasu, Thomas Van Blarcom, Javier Chaparro‐Riggers	38
9	Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery 2020 ·Molecular Therapy ·Cesar Sommer, Hsin‐Yuan Cheng, Duy Nguyen, (unknown), Yik A. Yeung, Janette Sutton, Moustafa Hamze, Julien Valton, Julianne Smith, Ivana M. Djuretic, Javier Chaparro‐Riggers, Barbra J. Sasu	70
10	Characterization and Comparison of GITR Expression in Solid Tumors 2019 ·Clinical Cancer Research ·Luis M. Vence, Samantha Bucktrout, Irina Fernandez Curbelo, Jorge Blando, (unknown), (unknown), John Lin, (unknown), Edward Pascua, Tao Sai, Javier Chaparro‐Riggers, Sumit K. Subudhi, Jorge Scutti, (unknown), Hao Zhao, Shalini S. Yadav, Anirban Maitra, Ignacio I. Wistuba, James P. Allison, Padmanee Sharma	38
11	Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity 2019 ·Cell Reports ·(unknown), Guang Huan Tu, Jie Wei, Pamela Santiago, (unknown), Sindy Liao-Chan, Tına Mistry, Matthew Ling-Hon Chu, Tao Sai, Kevin C. Lindquist, Hua Long, Javier Chaparro‐Riggers, Shahram Salek‐Ardakani, Yik A. Yeung	16
12	Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab 2018 ·Nature Communications ·Sherman M. Chin, Christopher R. Kimberlin, Zygy Roe-Žurž, (unknown), Allison Xu, Sindy Liao-Chan, Debasish Sen, Andrew R. Nager, (unknown), Colleen Brown, (unknown), Yuting Yang, Kevin C. Lindquist, Yik A. Yeung, Shahram Salek‐Ardakani, Javier Chaparro‐Riggers	95
13	Single nucleotide polymorphisms in the FcγR3A and TAP1 genes impact ADCC in cynomolgus monkey PBMCs 2017 ·Immunogenetics ·(unknown), Hong Wu, Yasmina Abdiche, (unknown), Javier Chaparro‐Riggers, Karissa Adkins	1
14	Preclinical Evaluation of a Potent Anti-Bcma CD3 Bispecific Molecule for the Treatment of Multiple Myeloma 2016 ·Blood ·Siler H. Panowski, Tracy C. Kuo, Amy Chen, (unknown), Thomas Van Blarcom, Kevin C. Lindquist, Wei Chen, Javier Chaparro‐Riggers, Barbra J. Sasu	19
15	Precise and Efficient Antibody Epitope Determination through Library Design, Yeast Display and Next-Generation Sequencing 2014 ·Journal of Molecular Biology ·Thomas Van Blarcom, Andrea Rossi, Davide Foletti, Purnima Sundar, Steven J. Pitts, Christine Bee, Jody Melton Witt, Zea Melton, Adela Hasa-Moreno, Lee Shaughnessy, Dilduz Telman, Lora Zhao, Wai Ling Cheung‐Lee, Jan Berka, Wenwu Zhai, Pavel Strop, Javier Chaparro‐Riggers, David L. Shelton, Jaume Pons, Arvind Rajpal	50
16	Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9 2012 ·Journal of Biological Chemistry ·Javier Chaparro‐Riggers, Liang Hong, Rachel M. DeVay, Lanfang Bai, Janette Sutton, Wei Chen, Tao Geng, Kevin C. Lindquist, Meritxell Galindo Casas, Leila M. Boustany, (unknown), J Chabot, Bruce Gomes, Pamela D. Garzone, Andrea Rossi, Pavel Strop, Dave Shelton, Jaume Pons, Arvind Rajpal	137
17	Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates 2011 ·Journal of Pharmacology and Experimental Therapeutics ·Liang Hong, Javier Chaparro‐Riggers, Pavel Strop, Tao Geng, Janette Sutton, Daniel Tsai, Lanfang Bai, Yasmina Abdiche, Jeanette Dilley, Jessica A. Yu, Si Wu, Sherman M. Chin, (unknown), Andrea Rossi, John Lin, Arvind Rajpal, Jaume Pons, David L. Shelton	90
18	Thermostable variants constructed via the structure-guided consensus method also show increased stability in salts solutions and homogeneous aqueous-organic media 2008 ·Protein Engineering Design and Selection ·(unknown), (unknown), James M. Broering, Javier Chaparro‐Riggers, Andreas S. Bommarius	63
19	Revealing biases inherent in recombination protocols 2007 ·BMC Biotechnology ·Javier Chaparro‐Riggers, (unknown), Karen M. Polizzi, (unknown), Xiao-Song Tang, Mark Nelson, Andreas S. Bommarius	9
20	Better library design: data‐driven protein engineering 2006 ·Biotechnology Journal ·Javier Chaparro‐Riggers, Karen M. Polizzi, Bettina Bommarius	67

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact